News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
394,018 Results
Type
Article (18786)
Company Profile (113)
Press Release (375119)
Section
Business (120967)
Career Advice (709)
Deals (23584)
Drug Delivery (78)
Drug Development (56250)
Employer Resources (67)
FDA (9789)
Job Trends (8556)
News (214203)
Policy (19859)
Tag
Academia (899)
Alliances (30103)
Alzheimer's disease (777)
Approvals (9804)
Artificial intelligence (129)
Bankruptcy (222)
Best Places to Work (6611)
Breast cancer (129)
Cancer (1118)
Cardiovascular disease (85)
Career advice (620)
CAR-T (79)
Cell therapy (220)
Clinical research (46677)
Collaboration (409)
Compensation (163)
COVID-19 (1200)
C-suite (108)
Data (1180)
Diabetes (129)
Diagnostics (3091)
Drug pricing (76)
Earnings (50664)
Events (56652)
Executive appointments (373)
FDA (10404)
Funding (313)
Gene therapy (168)
GLP-1 (401)
Government (2107)
Healthcare (8287)
Infectious disease (1257)
Inflammatory bowel disease (83)
Interviews (97)
IPO (10851)
Job creations (2314)
Job search strategy (552)
Layoffs (200)
Legal (4392)
Lung cancer (165)
Lymphoma (82)
Manufacturing (164)
Medical device (5401)
Medtech (5404)
Mergers & acquisitions (13046)
Metabolic disorders (346)
Neuroscience (1036)
NextGen: Class of 2025 (2678)
Non-profit (1203)
Northern California (1291)
Obesity (191)
Opinion (150)
Parkinson's disease (77)
Patents (130)
People (34925)
Phase I (14082)
Phase II (20491)
Phase III (15925)
Pipeline (545)
Postmarket research (1642)
Preclinical (5466)
Radiopharmaceuticals (165)
Rare diseases (218)
Real estate (3177)
Regulatory (14440)
Research institute (943)
Resumes & cover letters (89)
Southern California (1156)
Startups (1986)
United States (11585)
Vaccines (231)
Weight loss (131)
Date
Today (12)
Last 7 days (395)
Last 30 days (1718)
Last 365 days (22760)
2025 (2927)
2024 (23161)
2023 (26078)
2022 (33043)
2021 (34276)
2020 (32185)
2019 (23603)
2018 (17974)
2017 (20129)
2016 (18371)
2015 (22004)
2014 (16825)
2013 (13797)
2012 (14600)
2011 (15378)
2010 (14158)
Location
Africa (419)
Arizona (78)
Asia (28168)
Australia (5691)
California (2943)
Canada (1235)
China (293)
Colorado (142)
Connecticut (159)
Europe (54059)
Florida (451)
Illinois (254)
Indiana (162)
Japan (99)
Maryland (414)
Massachusetts (2319)
Minnesota (146)
New Jersey (1019)
New York (902)
North Carolina (537)
Northern California (1291)
Ohio (78)
Pennsylvania (735)
South America (664)
Southern California (1156)
Texas (430)
Virginia (78)
Washington State (346)
394,018 Results for "neuren pharmaceuticals limited".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Neuren Phase 2 trial shows significant improvements in Pitt Hopkins syndrome
Neuren Pharmaceuticals announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Pitt Hopkins syndrome.
May 27, 2024
·
8 min read
Drug Development
Neuren Phase 2 trial shows significant improvements in Phelan-McDermid syndrome
Neuren Pharmaceuticals (ASX: NEU) today announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Phelan-McDermid syndrome (PMS).
December 18, 2023
·
7 min read
Deals
Acadia Pharmaceuticals Acquires Ex-North American Rights to Trofinetide and Global Rights to Neuren’s NNZ-2591 in Rett Syndrome and Fragile X Syndrome
Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that it has expanded its current licensing agreement for trofinetide with Neuren Pharmaceuticals to acquire ex-North American rights to the drug as well as global rights in Rett syndrome and Fragile X syndrome to Neuren’s development candidate NNZ-2591.
July 13, 2023
·
11 min read
Press Releases
Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF®
February 11, 2025
·
8 min read
Deals
Telix Pharmaceuticals Limited completes the acquisition of ARTMS, Inc.
ARTMS Inc. (ARTMS) is pleased to announce that the acquisition by Telix Pharmaceuticals Limited (Telix) has been completed.
April 11, 2024
·
3 min read
BioCapital
Vanda Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan
Vanda Pharmaceuticals Inc. announced that its Board of Directors has adopted a limited duration stockholder rights plan to protect stockholder interests and maximize value for all stockholders.
April 17, 2024
·
5 min read
Aurigene Pharmaceutical Services Limited, a global CRDMO, announces the opening of its biologics facility offering process development and clinical scale manufacturing capabilities
Aurigene Pharmaceutical Services Limited (“Aurigene”), a Dr. Reddy’s Laboratories Limited company, inaugurated its biologics facility spread across 70,000 sq.ft. in Genome Valley
June 3, 2024
·
4 min read
Press Releases
Dynavax Adopts Limited-Duration Stockholder Rights Plan
October 30, 2024
·
5 min read
Press Releases
IMFINZI® (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer
December 5, 2024
·
19 min read
Cancer
BMS’ Phase III Opdualag Melanoma Fail Could Limit Market Opportunity: Analysts
The failure in adjuvant melanoma could cause BMS and Opdualag to miss out on a market opportunity that is nearly twice as large as its current approved indication, according to analysts.
February 14, 2025
·
2 min read
·
Tristan Manalac
1 of 39,402
Next
